MPWT
SMMT icon

MassMutual Private Wealth & Trust’s Summit Therapeutics SMMT Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$89 – 2488
2026
Q1 		$95 Buy
+5
New +$81 ﹤0.01% 2359

Other funds holding SMMT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $1B AUM 33.02% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
WMP
Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MassMutual Private Wealth & Trust's SMMT Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 5 shares — an estimated $89 sold.

MassMutual Private Wealth & Trust first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $95 in Q1 2026. 47 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 5 Summit Therapeutics shares in Q2 2026, an estimated $89.
  • MassMutual Private Wealth & Trust first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Summit Therapeutics position peaked at $95 in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.